Hyivy Device in Endometriosis

Endometriosis Clinical Trial

— endometriosis  

Official title:

Evaluation of the Hyivy Device as a Non-hormonal Therapy in People With Endometriosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05643131
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 30, 2024
• Est. completion date: June 1, 2025

Study information

• Verified date: February 2024
• Source: Hyivy Health Inc
• Contact: Kyle McGowan, H.B.Sc
• Phone: 905-521-2100
• Email: mcgowank[@]mcmaster.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the effect of using the Hyivy device on overall self-reported pelvic pain in people with endometriosis

Description:

Prior to study enrollment, all prospective participants will have the ability to contact the study team to learn more about the study and be provided with the relevant study-specific information. After being informed about the study and potential risks, all participants giving written informed consent will be assessed for their eligibility for the study, and enrolled participants will undergo a maximum 30-day screening period. On Day 0, eligible participants will start a 12-week use of Hyivy device with one visit on Week 6-7 and another on Week 12. After completing the 12-week intervention period, a virtual follow-up will be conducted on Week 16.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: June 1, 2025
• Est. primary completion date: February 1, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1.Age = 18 at the time of enrollment
• 2.Generally in good health (other than due to endometriosis), at physician's discretion
• 3.Diagnosed with endometriosis (clinical, radiologic, or surgical)
• 4.Diagnosed with chronic pelvic pain (self-reported pain in pelvic area lasting >3 months)
• 5.VAS for overall pelvic pain = 4 at screening and baseline
• 6.Medically managing endometriosis using continuous hormonal medications (i.e., oral contraceptive pills, progesterone only pills, Mirena, GnRH agonists/antagonists) for at least 3 months prior to enrollment
• 7.Agrees not to commence any new treatments (medical or physical therapies) for the 12-week intervention period
• 8.Agrees not to undergo pelvic physiotherapy with a trained professional during the study
• 9.Must have the ability to charge the investigational device
• 10.Must be willing and able to insert intravaginal device
• 11.Able to understand, comply and consent to protocol requirements and instructions
• 12.Able to attend scheduled study visits and complete required investigations

Exclusion Criteria:

• 1.Chronic pelvic pain thought to be due to a condition other than endometriosis
• 2.Diagnosis of premature ovarian insufficiency
• 3.Has a condition rendering them unable to understand the nature, scope and possible consequences of the study, or evidence of an uncooperative attitude
• 4.Any surgery in the past 3 months or anticipates having surgery during the study
• 5.Allergy to Hyivy device's materials
• 6.Active vaginal infection (e.g. vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis, STIs)
• 7.Current use of antibiotics and a history of vulvovaginal candidiasis
• 8.Pregnant or lactating
• 9.Currently under the care of a pelvic floor physiotherapist Pre-study washout: If potential study participants are pregnant, lactating, or initiating hormonal contraceptives, their eligibility to participate in the study can be re-evaluated after 3 months of hormonal contraceptive use prior to enrollment. If potential study participants have an active vaginal infection or are currently using antibiotics with a history of vulvovaginal candidiasis, their eligibility to participate in the study can be re-evaluated after treatment, and resolution of the infection.

Related Conditions & MeSH terms

• Endometriosis
• Pelvic Pain

Intervention

Device:
• Hyivy device
Intravaginal use of Hyivy device three times per week for 12 weeks, with each use session consisting of: 10 minutes of heat (37-42ºC) and 10 minutes of dilation

Locations

Country	Name	City	State
Canada	McMaster University Medical Centre	Hamilton	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Hyivy Health Inc	McMaster University

Country where clinical trial is conducted

Canada, 

References & Publications (49)

Adamson, G.D., S. Kennedy, and L. Hummelshoj, Creating Solutions in Endometriosis: Global Collaboration through the World Endometriosis Research Foundation. Journal of Endometriosis, 2010. 2(1): p. 3-6.

Ahangari A. Prevalence of chronic pelvic pain among women: an updated review. Pain Physician. 2014 Mar-Apr;17(2):E141-7. — View Citation

Araya-Castro P, Sacomori C, Diaz-Guerrero P, Gayan P, Roman D, Sperandio FF. Vaginal Dilator and Pelvic Floor Exercises for Vaginal Stenosis, Sexual Health and Quality of Life among Cervical Cancer Patients Treated with Radiation: Clinical Report. J Sex Marital Ther. 2020;46(6):513-527. doi: 10.1080/0092623X.2020.1760981. Epub 2020 May 2. — View Citation

Armour M, Lawson K, Wood A, Smith CA, Abbott J. The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey. PLoS One. 2019 Oct 10;14(10):e0223316. doi: 10.1371/journal.pone.0223316. eCollection 2019. — View Citation

Armour M, Sinclair J, Chalmers KJ, Smith CA. Self-management strategies amongst Australian women with endometriosis: a national online survey. BMC Complement Altern Med. 2019 Jan 15;19(1):17. doi: 10.1186/s12906-019-2431-x. — View Citation

Armour M, Sinclair J, Noller G, Girling J, Larcombe M, Al-Dabbas MA, Hollow E, Bush D, Johnson N. Illicit Cannabis Usage as a Management Strategy in New Zealand Women with Endometriosis: An Online Survey. J Womens Health (Larchmt). 2021 Oct;30(10):1485-1492. doi: 10.1089/jwh.2020.8668. Epub 2020 Dec 3. — View Citation

Armour M, Smith CA, Schabrun S, Steiner GZ, Zhu X, Lawson K, Song J. Manual acupuncture plus usual care versus usual care alone in the treatment of endometriosis-related chronic pelvic pain: study protocol for a randomised controlled feasibility study. Pilot Feasibility Stud. 2017 Jul 6;4:10. doi: 10.1186/s40814-017-0152-9. eCollection 2018. Erratum In: Pilot Feasibility Stud. 2017 Oct 24;3:48. — View Citation

As-Sanie S, Black R, Giudice LC, Gray Valbrun T, Gupta J, Jones B, Laufer MR, Milspaw AT, Missmer SA, Norman A, Taylor RN, Wallace K, Williams Z, Yong PJ, Nebel RA. Assessing research gaps and unmet needs in endometriosis. Am J Obstet Gynecol. 2019 Aug;221(2):86-94. doi: 10.1016/j.ajog.2019.02.033. Epub 2019 Feb 18. — View Citation

Aslan M, Yavuzkir S, Baykara S. Is "Dilator Use" More Effective Than "Finger Use" in Exposure Therapy in Vaginismus Treatment? J Sex Marital Ther. 2020;46(4):354-360. doi: 10.1080/0092623X.2020.1716907. Epub 2020 Feb 13. — View Citation

Ayorinde AA, Macfarlane GJ, Saraswat L, Bhattacharya S. Chronic pelvic pain in women: an epidemiological perspective. Womens Health (Lond). 2015 Nov;11(6):851-64. doi: 10.2217/whe.15.30. Epub 2015 Oct 9. — View Citation

Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017 Jul;108(1):125-136. doi: 10.1016/j.fertnstert.2017.05.004. — View Citation

Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol. 1981 Mar 15;139(6):645-54. doi: 10.1016/0002-9378(81)90478-6. — View Citation

Brady PC, Horne AW, Saunders PTK, Thomas AM, Missmer SA, Farland LV. Research priorities for endometriosis differ among patients, clinicians, and researchers. Am J Obstet Gynecol. 2020 Jun;222(6):630-632. doi: 10.1016/j.ajog.2020.02.047. Epub 2020 Mar 3. No abstract available. — View Citation

De Graaff AA, D'Hooghe TM, Dunselman GA, Dirksen CD, Hummelshoj L; WERF EndoCost Consortium; Simoens S. The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. Hum Reprod. 2013 Oct;28(10):2677-85. doi: 10.1093/humrep/det284. Epub 2013 Jul 11. — View Citation

Del Forno S, Arena A, Alessandrini M, Pellizzone V, Lenzi J, Raimondo D, Casadio P, Youssef A, Paradisi R, Seracchioli R. Transperineal Ultrasound Visual Feedback Assisted Pelvic Floor Muscle Physiotherapy in Women With Deep Infiltrating Endometriosis and Dyspareunia: A Pilot Study. J Sex Marital Ther. 2020;46(7):603-611. doi: 10.1080/0092623X.2020.1765057. Epub 2020 Jun 24. — View Citation

Del Forno S, Arena A, Pellizzone V, Lenzi J, Raimondo D, Cocchi L, Paradisi R, Youssef A, Casadio P, Seracchioli R. Assessment of levator hiatal area using 3D/4D transperineal ultrasound in women with deep infiltrating endometriosis and superficial dyspareunia treated with pelvic floor muscle physiotherapy: randomized controlled trial. Ultrasound Obstet Gynecol. 2021 May;57(5):726-732. doi: 10.1002/uog.23590. — View Citation

Delgado D, White P, Trochez R, Drake MJ. A pilot randomised controlled trial of the pelvic toner device in female stress urinary incontinence. Int Urogynecol J. 2013 Oct;24(10):1739-45. doi: 10.1007/s00192-013-2107-x. Epub 2013 May 3. — View Citation

Duffy J, Hirsch M, Vercoe M, Abbott J, Barker C, Collura B, Drake R, Evers J, Hickey M, Horne AW, Hull ML, Kolekar S, Lensen S, Johnson NP, Mahajan V, Mol BW, Otter AS, Puscasiu L, Rodriguez MB, Rombauts L, Vail A, Wang R, Farquhar CM; endo:outcomes - an International Collaboration Harmonising Outcomes and Outcome Measures for Endometriosis Research. A core outcome set for future endometriosis research: an international consensus development study. BJOG. 2020 Jul;127(8):967-974. doi: 10.1111/1471-0528.16157. Epub 2020 Mar 30. — View Citation

Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. Health Qual Life Outcomes. 2010 Nov 24;8:138. doi: 10.1186/1477-7525-8-138. — View Citation

Ghaderi F, Bastani P, Hajebrahimi S, Jafarabadi MA, Berghmans B. Pelvic floor rehabilitation in the treatment of women with dyspareunia: a randomized controlled clinical trial. Int Urogynecol J. 2019 Nov;30(11):1849-1855. doi: 10.1007/s00192-019-04019-3. Epub 2019 Jul 8. — View Citation

Goncalves AV, Barros NF, Bahamondes L. The Practice of Hatha Yoga for the Treatment of Pain Associated with Endometriosis. J Altern Complement Med. 2017 Jan;23(1):45-52. doi: 10.1089/acm.2015.0343. Epub 2016 Nov 21. — View Citation

Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014 Mar 19;348:g1752. doi: 10.1136/bmj.g1752. No abstract available. — View Citation

Horne AW, Saunders PTK, Abokhrais IM, Hogg L; Endometriosis Priority Setting Partnership Steering Group (appendix). Top ten endometriosis research priorities in the UK and Ireland. Lancet. 2017 Jun 3;389(10085):2191-2192. doi: 10.1016/S0140-6736(17)31344-2. Epub 2017 May 18. No abstract available. — View Citation

Johnson N, Miles TP, Cornes P. Dilating the vagina to prevent damage from radiotherapy: systematic review of the literature. BJOG. 2010 Apr;117(5):522-31. doi: 10.1111/j.1471-0528.2010.02502.x. Epub 2010 Feb 16. — View Citation

Jones G, Kennedy S, Barnard A, Wong J, Jenkinson C. Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30. Obstet Gynecol. 2001 Aug;98(2):258-64. doi: 10.1016/s0029-7844(01)01433-8. — View Citation

Kong S, Zhang YH, Liu CF, Tsui I, Guo Y, Ai BB, Han FJ. The complementary and alternative medicine for endometriosis: a review of utilization and mechanism. Evid Based Complement Alternat Med. 2014;2014:146383. doi: 10.1155/2014/146383. Epub 2014 Feb 19. — View Citation

Law E, Kelvin JF, Thom B, Riedel E, Tom A, Carter J, Alektiar KM, Goodman KA. Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. Radiother Oncol. 2015 Jul;116(1):149-55. doi: 10.1016/j.radonc.2015.06.018. Epub 2015 Jul 8. — View Citation

Levy AR, Osenenko KM, Lozano-Ortega G, Sambrook R, Jeddi M, Belisle S, Reid RL. Economic burden of surgically confirmed endometriosis in Canada. J Obstet Gynaecol Can. 2011 Aug;33(8):830-837. doi: 10.1016/S1701-2163(16)34986-6. — View Citation

Lukas I, Kohl-Schwartz A, Geraedts K, Rauchfuss M, Wolfler MM, Haberlin F, von Orelli S, Eberhard M, Imthurn B, Imesch P, Leeners B. Satisfaction with medical support in women with endometriosis. PLoS One. 2018 Nov 29;13(11):e0208023. doi: 10.1371/journal.pone.0208023. eCollection 2018. — View Citation

Malanga GA, Yan N, Stark J. Mechanisms and efficacy of heat and cold therapies for musculoskeletal injury. Postgrad Med. 2015 Jan;127(1):57-65. doi: 10.1080/00325481.2015.992719. Epub 2014 Dec 15. — View Citation

Marques A, Stothers L, Macnab A. The status of pelvic floor muscle training for women. Can Urol Assoc J. 2010 Dec;4(6):419-24. doi: 10.5489/cuaj.10026. — View Citation

Monsanto SP, Edwards AK, Zhou J, Nagarkatti P, Nagarkatti M, Young SL, Lessey BA, Tayade C. Surgical removal of endometriotic lesions alters local and systemic proinflammatory cytokines in endometriosis patients. Fertil Steril. 2016 Apr;105(4):968-977.e5. doi: 10.1016/j.fertnstert.2015.11.047. Epub 2015 Dec 14. — View Citation

Moore JS, Gibson PR, Perry RE, Burgell RE. Endometriosis in patients with irritable bowel syndrome: Specific symptomatic and demographic profile, and response to the low FODMAP diet. Aust N Z J Obstet Gynaecol. 2017 Apr;57(2):201-205. doi: 10.1111/ajo.12594. Epub 2017 Mar 17. — View Citation

Nadler SF, Weingand K, Kruse RJ. The physiologic basis and clinical applications of cryotherapy and thermotherapy for the pain practitioner. Pain Physician. 2004 Jul;7(3):395-9. — View Citation

Nnoaham KE, Hummelshoj L, Webster P, d'Hooghe T, de Cicco Nardone F, de Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT; World Endometriosis Research Foundation Global Study of Women's Health consortium. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011 Aug;96(2):366-373.e8. doi: 10.1016/j.fertnstert.2011.05.090. Epub 2011 Jun 30. — View Citation

Ong TA, Khong SY, Ng KL, Ting JR, Kamal N, Yeoh WS, Yap NY, Razack AH. Using the Vibrance Kegel Device With Pelvic Floor Muscle Exercise for Stress Urinary Incontinence: A Randomized Controlled Pilot Study. Urology. 2015 Sep;86(3):487-91. doi: 10.1016/j.urology.2015.06.022. Epub 2015 Jul 2. Erratum In: Urology. 2017 Jan;99:294. — View Citation

Reinert, A.E. and M. Hibner, Self-Reported Efficacy of Cannabis for Endometriosis Pain. Journal of Minimally Invasive Gynecology, 2019. 26(7 Supplement): p. S72.

Rogers PA, Adamson GD, Al-Jefout M, Becker CM, D'Hooghe TM, Dunselman GA, Fazleabas A, Giudice LC, Horne AW, Hull ML, Hummelshoj L, Missmer SA, Montgomery GW, Stratton P, Taylor RN, Rombauts L, Saunders PT, Vincent K, Zondervan KT; WES/WERF Consortium for Research Priorities in Endometriosis. Research Priorities for Endometriosis. Reprod Sci. 2017 Feb;24(2):202-226. doi: 10.1177/1933719116654991. Epub 2016 Sep 27. — View Citation

Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. doi: 10.1080/009262300278597. — View Citation

Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, Brodszky V, Canis M, Colombo GL, DeLeire T, Falcone T, Graham B, Halis G, Horne A, Kanj O, Kjer JJ, Kristensen J, Lebovic D, Mueller M, Vigano P, Wullschleger M, D'Hooghe T. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012 May;27(5):1292-9. doi: 10.1093/humrep/des073. Epub 2012 Mar 14. Erratum In: Hum Reprod. 2014 Sep;29(9):2073. — View Citation

Sinclair J, Smith CA, Abbott J, Chalmers KJ, Pate DW, Armour M. Cannabis Use, a Self-Management Strategy Among Australian Women With Endometriosis: Results From a National Online Survey. J Obstet Gynaecol Can. 2020 Mar;42(3):256-261. doi: 10.1016/j.jogc.2019.08.033. Epub 2019 Nov 10. — View Citation

Singh S, Soliman AM, Rahal Y, Robert C, Defoy I, Nisbet P, Leyland N. Prevalence, Symptomatic Burden, and Diagnosis of Endometriosis in Canada: Cross-Sectional Survey of 30 000 Women. J Obstet Gynaecol Can. 2020 Jul;42(7):829-838. doi: 10.1016/j.jogc.2019.10.038. Epub 2020 Jan 27. — View Citation

Singh SS, Gude K, Perdeaux E, Gattrell WT, Becker CM. Surgical Outcomes in Patients With Endometriosis: A Systematic Review. J Obstet Gynaecol Can. 2020 Jul;42(7):881-888.e11. doi: 10.1016/j.jogc.2019.08.004. Epub 2019 Nov 9. — View Citation

Tu FF, Holt J, Gonzales J, Fitzgerald CM. Physical therapy evaluation of patients with chronic pelvic pain: a controlled study. Am J Obstet Gynecol. 2008 Mar;198(3):272.e1-7. doi: 10.1016/j.ajog.2007.09.002. — View Citation

Vercellini P, Somigliana E, Vigano P, Abbiati A, Daguati R, Crosignani PG. Endometriosis: current and future medical therapies. Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):275-306. doi: 10.1016/j.bpobgyn.2007.10.001. Epub 2007 Nov 26. — View Citation

Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014 May;10(5):261-75. doi: 10.1038/nrendo.2013.255. Epub 2013 Dec 24. — View Citation

Whitaker LH, Reid J, Choa A, McFee S, Seretny M, Wilson J, Elton RA, Vincent K, Horne AW. An Exploratory Study into Objective and Reported Characteristics of Neuropathic Pain in Women with Chronic Pelvic Pain. PLoS One. 2016 Apr 5;11(4):e0151950. doi: 10.1371/journal.pone.0151950. eCollection 2016. — View Citation

Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020 Mar 26;382(13):1244-1256. doi: 10.1056/NEJMra1810764. No abstract available. — View Citation

Zondervan KT, Yudkin PL, Vessey MP, Jenkinson CP, Dawes MG, Barlow DH, Kennedy SH. Chronic pelvic pain in the community--symptoms, investigations, and diagnoses. Am J Obstet Gynecol. 2001 May;184(6):1149-55. doi: 10.1067/mob.2001.112904. — View Citation

* Note: There are 49 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall self-reported pelvic pain	Change in overall pelvic pain will be evaluated using a digital visual analog scale (VAS) ranging from 0 (no discomfort) to 10 (severe discomfort)	12 weeks
Secondary	site-specific tenderness and pelvic floor muscle pain	site-specific tenderness and pelvic floor muscle pain will be measured by Biberoglu and Behrman scale (B&B) ranging from 0 (none) to 15 (severe)	12 weeks
Secondary	changes in quality of life	changes in quality of life as assessed by the Endometriosis Health Profile-30 (EHP-30) ranging from 0 (best possible health status) to 100 (worst possible health status)	12 weeks
Secondary	sexual function	changes in sexual function as assessed by the Female Sexual Function Index (FSFI). The female sexual function index (FSFI) is a measure of sexual functioning in women. Scores range from 2 to 36 with higher scores indicating greater functioning.	12 weeks
Secondary	changes in the use of rescue medications and Emergency rooms visits	changes in the use of rescue medications and Emergency rooms visits as assessed by a study-specific questionnaire	12 weeks
Secondary	changes in peripheral inflammation	changes in Peripheral Inflammatory Protein Expression as assessed by an inflammatory multiplexed protein biomarker assay(a protein biomarker panel) from blood draw	12 weeks
Secondary	feasibility of the Hyivy device	feasibility of the Hyivy device as a non-hormonal therapy in people with endometriosis as evaluated by review of participant subjective questionnaires(such as device size, easy to insert, hold and remove).	12 weeks
Secondary	safety and tolerability of the Hyivy device assessed by the Number of participants with treatment-related adverse events as assessed by CTCAE v4.0)	safety and tolerability of the Hyivy device as a non-hormonal therapy in people with endometriosis as assessed by review of adverse events (AE) and serious adverse events (SAE).	12 weeks
Secondary	The adherence of the Hyivy device assessed by participants' compliance	adherence to the study regimen as assessed by comparing usage data collected by the Hyivy device to the recommended intervention regimen(adherence rate = # of times of patients did dilation therapy/# of times of patients should do dilation therapy *100%)	12 weeks
Secondary	The usability and satisfaction of the Hyivy device	The usability and satisfaction of the Hyivy device for Hyivy's product development as assessed by study-specific questionnaires ranging from 11 (worst usability and satisfaction) to 55 (best usability and satisfaction)	12 weeks